Cannabis-Induced ‘Scromiting’ Is on the Rise, Study Finds

A University of Illinois Chicago analysis of U.S. emergency-department data (2016–2022) identified roughly 100,000 suspected cases of cannabinoid hyperemesis syndrome (CHS) — characterized by cyclical, severe vomiting — with a marked surge beginning in 2020, peaking in 2021 and remaining above pre-pandemic levels in 2022. Investigators used co-occurring diagnoses of cyclical vomiting and cannabis use as a proxy for CHS; they cite COVID-related stress and increased cannabis use, broader legalization, and higher THC potency as potential drivers. CHS was added to the ICD this year, easing future tracking and diagnosis, which presents modest reputational, clinical-cost and regulatory risks for cannabis producers, retailers, and insurers but is unlikely to be materially market-moving in the near term.

Analysis

Market structure: Rising CHS ER visits create small, concentrated winners (ER/urgent-care operators, hospital systems, and coding/software vendors) and modestly negative demand pressure on high-THC product segments of cannabis MSOs. Expect a 1–5% demand hit to heavy-use concentrate categories over 6–12 months that compresses niche product pricing power but leaves broader recreational market largely intact. Cross-asset: expect higher implied vol for cannabis equities (puts demand), negligible sovereign bond or FX impact, and small cyclical lift for hospital equities over the next 3–12 months.

Risk assessment: Tail risks include state-level restrictions on high-THC products or class-action suits that could trigger 20–50% equity repricings for small, leveraged MSOs; probability low but material over 12–24 months. Immediate (days): headlines and ICD coding updates can move small-cap cannabis names 10–30%; short-term (weeks–months): consumer behavior shifts and retailer assortment changes; long-term (quarters–years): regulatory and product reformulation risk. Hidden dependencies: testing labs, packaging suppliers, and payment processors that serve concentrates are second-order exposures.

Trade implications: Favor small, tactical reallocation into defensive hospital/ER names (HCA, UHS) and into large diversified insurers (UNH) while trimming pure-play high-THC MSOs (TLRY, CURLF, CGC) via equity shorts or puts. Use 3–6 month option structures (put spreads) to cap cost on cannabis shorts and buy modest call exposure on HCA/UHS for 6–12 month horizons; target position sizes 1–3% NAV each. Rotate 2–4% of consumer/cannabis allocation into healthcare services over next 90 days.

Contrarian angle: Consensus treats CHS as a niche health story; that underestimates persistent reputational risk that can drive consolidation and create M&A targets among well-capitalized MSOs. Historical parallel: vaping scares caused 20–40% drawdowns then selective recovery—expect disproportionate dislocations among small caps rather than broad-sector collapse. If two+ states or CDC issue restrictive guidance within 90 days, re-rate positions: enlarge shorts and scout acquisition targets at -30% dislocations.

Key Decisions for Investors

• Establish a 1–2% NAV long position in HCA (HCA) or UHS (UHS) within 30 days, target +20% total return over 6–12 months, stop-loss at -10% to capture modest ER volume/pricing tailwinds from CHS visibility.
• Implement a 1% NAV bearish hedge on cannabis pure-plays: buy 3–6 month put spreads on TLRY (Tilray) sized to cost ~0.2–0.4% NAV (choose strikes ~25–35% OTM) or short 1–2% NAV of CURLF/CGC if liquidity allows; take profits at -30% relative underperformance or widen if regulatory catalysts appear.
• Execute a pair trade: long 1% NAV UNH (UnitedHealth) vs short 1% NAV TLRY as a relative-value defensive/volatile cannabis play; rebalance if TLRY outperforms/underperforms by >15% within 90 days.
• Monitor and use regulatory triggers: if within 90 days two U.S. states or CDC issue advisories/limitations on high-THC products, increase short exposure to 3–4% NAV and add 6–12 month call protection on chosen hospital names (HCA/UHS) to lock downside.